CG Labz
Peptide Library / Growth Hormone / Metabolic

Tesamorelin

Stabilized GHRH analog

Tesamorelin Research Protocol

Complete Research Guide 4 min read1 peer-reviewed references

Quickstart Overview

Tesamorelin is a stabilized GHRH analog (a trans-3-hexenoyl modification of GRF 1-44) approved clinically to reduce excess visceral adipose tissue. It stimulates pulsatile GH release and is the most clinically validated GHRH analog for central-fat reduction.

Reconstitution
Add 2.0 mL bacteriostatic water to a 5 mg vial → 2.5 mg/mL
Clinical Dose
2 mg once daily
Measuring Reference
At 2.5 mg/mL: 1 mg = 0.4 mL = 40 units
Frequency
Once daily
Route (studies)
Subcutaneous
Focus
Visceral fat reduction

Scientific Data

Molecular Formula
—
Molecular Weight
5135.9 Da
Sequence
Trans-3-hexenoyl-GRF(1-44)
Sequence Length
16
CAS
Research compound
Peptide Family
GHRH analog
Half-life
Refer to published literature
Solubility
Bacteriostatic water, sterile saline
Storage
Lyophilized: -20°C. Reconstituted: 2–8°C, use within 2–4 weeks.
Appearance
White lyophilized powder
Standard: 5 mg vial · 2 mL diluent

Dosing & Reconstitution Guide

Interactive Reconstitution
Adjust vial size, diluent and target dose. Results update live.
Full Precision Calculator →
Concentration
2.50 mg/mL
Draw Volume
0.400 mL
Syringe Units
40.0 U
Doses / Vial
5

Units assume a U-100 insulin syringe (100 units = 1 mL). The most clinically validated GHRH analog for visceral-fat reduction.

Frequency: Nightly, fasted

Reconstitution Steps

  1. 1Allow the lyophilized vial and bacteriostatic water to reach room temperature (~15 min).
  2. 2Swab both vial stoppers with a fresh 70% isopropyl alcohol pad and let them dry.
  3. 3Draw 2.0 mL of bacteriostatic water into a mixing syringe.
  4. 4Insert at an angle and let the water run slowly down the glass wall — never directly onto the powder.
  5. 5Gently swirl (do not shake) until the solution is completely clear.
  6. 6Label with date and concentration (mg/mL) and refrigerate at 2–8 °C immediately.

Supplies Needed

Planning example for a 16-week protocol at approximately 1000 mcg per day.

Peptide (5 mg vials)
Estimate vials from total mass: 1000 mcg/day × 112 days.
Bacteriostatic Water
One 10–30 mL vial typically covers a full cycle.
Insulin Syringes (U-100)
One per administration (29–31 G, 0.3–0.5 mL).
Alcohol Swabs
Two per administration (vial + site).
Sharps Container
Required for safe disposal.

Protocol Overview

Goal
Model GHRH-driven GH release with a focus on visceral-fat reduction.
Schedule
Daily, 12–24 weeks.
Dose Range
1–2 mg/day.

Dosing Protocol

Standard
1–2 mg once daily
Frequency
Nightly, fasted
Target
2 mg/day is the clinically studied dose
Cycle Length
12–24 weeks
Timing
Pre-bed, fasted
Route
Subcutaneous abdomen

Storage Instructions

Lyophilized
−20 °C long term (18–24 months); stable at room temperature for short transit.
Reconstituted
2–8 °C refrigerated; use within 4 weeks.
Light
Protect from direct light; keep in the original carton.
Freeze/Thaw
Avoid repeat freeze–thaw cycles after reconstitution.

Important Notes

  • Monitor IGF-1 and glucose tolerance in extended protocols.
  • Fluid retention and joint symptoms are the common dose-related effects.

How This Works

Tesamorelin binds pituitary GHRH receptors to stimulate synthesis and pulsatile release of growth hormone, raising IGF-1. Its defining clinical feature is a selective reduction of visceral (intra-abdominal) fat, demonstrated in trials in HIV-associated lipodystrophy, with accompanying improvements in triglycerides. The N-terminal modification protects it from rapid enzymatic degradation.

Potential Benefits & Side Effects

Reported in research
  • Clinically proven reduction in visceral adipose tissue
  • Raised IGF-1 and GH in a pulsatile pattern
  • Improved triglyceride and lipid profiles
  • Possible cognitive benefits studied in aging cohorts
Possible considerations
  • Injection-site reactions (common)
  • Arthralgia and peripheral oedema
  • Fluid retention and carpal-tunnel-like symptoms
  • Raised IGF-1 — monitor in longer use
  • Can affect glucose tolerance

Lifestyle Factors

  • Adequate hydration and 7–9 h of sleep are standard controls in most research protocols.
  • Consistent dose timing improves the reliability of any self-tracked endpoints.
  • Maintain a clean, sterile workflow for every draw to avoid contamination.

Injection Technique

  1. 1Wash hands, then prep the vial top and the target site with separate alcohol swabs.
  2. 2Pinch a subcutaneous skin fold (abdomen, ~2 inches from the navel) and insert at 45–90°.
  3. 3Depress the plunger slowly over 3–5 seconds, hold 5 seconds, then withdraw.
  4. 4Rotate sites each administration and dispose of the syringe in a sharps container.

Frequently Asked Questions

Third-party HPLC testing

CG Labz Verified Batches

No published batches yet.

Research Disclaimer

All compounds are supplied strictly for laboratory research. Dosing figures below summarize ranges reported in published preclinical and clinical literature for reference purposes only. CG Labz does not provide medical advice or individualized dosing recommendations.

Peer-reviewed literature

References

  1. [1] New England Journal of Medicine
    Falutz J. et al. Tesamorelin, a GHRH analogue, in patients with abdominal fat accumulation.
    View Source